European Profile of Hepatitis Delta and Bulevirtide

The International Profile of Hepatitis DeltaПодробнее

Update on the Efficacy and Safety of Bulevirtide for Treatment of Chronic HDV - D. Manuilov, MDПодробнее

Clinical Trial: Bulevirtide for Chronic Hepatitis Delta (NCT03852719)Подробнее

HDV, the most severe form of viral hepatitis. What you need to know about itПодробнее

EASL Policy Dialogue — World Hepatitis Day - Spotlight on Hepatitis D — Season 2, Episode 4Подробнее

Hepatitis Delta Rare Disease DayПодробнее

Hepatitis Delta The Hidden EpidemicПодробнее

The Scientific Journey of Bulevirtide: Discovery, Development, and Mode of ActionПодробнее

Hepatitis Delta 101 Train-the-Trainer PresentationПодробнее

ECHO 2022 Session 14: Hepatitis DeltaПодробнее

Pietro Lampertico | Global HDV Elimination: Challenges and OpportunitiesПодробнее

ECHO 2023 Session 24: Hepatitis Delta Epidemiology, Virology, and Treatment LandscapeПодробнее

Dr. Stephan Urban: 2023 Baruch S. Blumberg Prize Recipient SeminarПодробнее

Hepatitis Delta | Mario Rizetto, MDПодробнее

Intrahepatic Landscape in the Delta-Infected, Bulevirtide-Treated Liver - Maura Dandri, PhDПодробнее

Patient-Reported Outcomes in Chronic Hepatitis Delta with Dr. Maria ButiПодробнее

Entry Inhibitors for HBV and HDV (Bulevirtide) - Stephan UrbanПодробнее

Hepatitis Delta Virus: Overview and Latest TreatmentsПодробнее